The Brand Name RIDRO-M Has Generic Salt :: Mefenamic
RIDRO-M Is From Company RISHAB(OROCHEM) Priced :: Rs. 49
RIDRO-M have Mefenamic is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Mefenamic | TAB | Rs. 49 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| RIDRO-M | RISHAB(OROCHEM) | 80,250;MG | 10 | Rs. 49 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From RISHAB(OROCHEM) :: RIDRO-M | Mefenamic | #N/A | #N/A |
Indications for Drugs ::
Rheumatoid arthritis, Osteoarthritis, Dysmenorrhoea, Menorrhagia, Dental pain, Pain and inflammation, Mild to moderate pain, Postoperative pain
Drug Dose ::
Oral Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia Adult: 500 mg tid. Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
Contraindication ::
Inflammatory bowel disease; peptic ulcer; neonates; pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure.
Drug Precautions ::
Renal and hepatic impairment, asthma. Monitor blood counts and liver function during long-term therapy. Drowsiness may affect ability to perform skilled tasks. Elderly.
Drug Side Effects ::
Abdominal pain, dyspepsia, constipation, diarrhoea, nausea, GI ulcers; oedema; bronchospasm; headache, drowsiness, insomnia, visual disturbances; CHF, hypertension, tachycardia, syncope; urticaria, rash; thrombocytopenia, aplastic anaemia, agranulocytosis; tinnitus; elevated liver enzymes; abnormal renal function. Potentially Fatal: Autoimmune haemolytic anaemia; convulsions (overdosage).
Pregnancy category ::
4
Drug Mode of Action ::
Oral Rheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia Adult: 500 mg tid. Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
Drug Interactions ::
Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.